ZA201708037B - Sprinkle formulations of acamprosate - Google Patents
Sprinkle formulations of acamprosateInfo
- Publication number
- ZA201708037B ZA201708037B ZA2017/08037A ZA201708037A ZA201708037B ZA 201708037 B ZA201708037 B ZA 201708037B ZA 2017/08037 A ZA2017/08037 A ZA 2017/08037A ZA 201708037 A ZA201708037 A ZA 201708037A ZA 201708037 B ZA201708037 B ZA 201708037B
- Authority
- ZA
- South Africa
- Prior art keywords
- acamprosate
- sprinkle formulations
- sprinkle
- formulations
- Prior art date
Links
- AFCGFAGUEYAMAO-UHFFFAOYSA-N acamprosate Chemical compound CC(=O)NCCCS(O)(=O)=O AFCGFAGUEYAMAO-UHFFFAOYSA-N 0.000 title 1
- 229960004047 acamprosate Drugs 0.000 title 1
- 238000009472 formulation Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/009—Sachets, pouches characterised by the material or function of the envelope
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
- A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Zoology (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Psychiatry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hospice & Palliative Care (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562156842P | 2015-05-04 | 2015-05-04 | |
| US201562260161P | 2015-11-25 | 2015-11-25 | |
| PCT/US2016/030725 WO2016179252A1 (en) | 2015-05-04 | 2016-05-04 | Sprinkle formulations of acamprosate |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA201708037B true ZA201708037B (en) | 2020-03-25 |
Family
ID=57217823
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA2017/08037A ZA201708037B (en) | 2015-05-04 | 2017-11-27 | Sprinkle formulations of acamprosate |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US10709668B2 (enExample) |
| EP (1) | EP3291800A4 (enExample) |
| JP (2) | JP7026347B2 (enExample) |
| KR (1) | KR102790656B1 (enExample) |
| AU (1) | AU2016258624B2 (enExample) |
| HK (1) | HK1252003A1 (enExample) |
| IL (1) | IL255343B2 (enExample) |
| SG (1) | SG11201708393UA (enExample) |
| WO (1) | WO2016179252A1 (enExample) |
| ZA (1) | ZA201708037B (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016132136A1 (en) | 2015-02-18 | 2016-08-25 | Aston University | Diagnostic assay and treatment for preeclampsia |
| KR102790656B1 (ko) | 2015-05-04 | 2025-04-02 | 컨플루언스 파마슈티컬스, 엘엘씨 | 아캄프로세이트의 스프링클 제형 |
| AU2016303610A1 (en) * | 2015-08-04 | 2018-02-01 | Confluence Pharmaceuticals, Llc | Combination therapy using acamprosate and D-cycloserine |
| EP3624788A4 (en) * | 2017-05-17 | 2021-03-03 | Confluence Pharmaceuticals, LLC | FORMULATIONS OF HOMOTAURIN AND SALT THEREOF |
| ES2938609T3 (es) * | 2017-09-20 | 2023-04-13 | Tillotts Pharma Ag | Preparación de formas farmacéuticas sólidas que comprenden anticuerpos mediante estratificación de solución/suspensión |
| EP4213817A1 (en) * | 2020-09-21 | 2023-07-26 | Sun Pharmaceutical Industries Limited | Multi-particulate pharmaceutical composition of quetiapine |
| US20240382133A1 (en) | 2021-09-24 | 2024-11-21 | Sumitomo Bakelite Co., Ltd. | Brain wave detection electrode, brain wave measuring device, and brain wave measuring method |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6514530B2 (en) | 1997-09-09 | 2003-02-04 | Alza Corporation | Dosage form comprising means for changing drug delivery shape |
| AU765603C (en) | 1998-04-14 | 2004-08-05 | General Hospital Corporation, The | Methods for treating neuropsychiatric disorders |
| RU2375048C2 (ru) * | 2003-07-17 | 2009-12-10 | Д-Р Редди'С Лабораторис Инк. | Фармацевтическая композиция с набухающим покрытием |
| DE102007009243A1 (de) | 2007-02-22 | 2008-09-18 | Evonik Röhm Gmbh | Pellets mit einer Wirkstoff-Matrix und einem Polymerüberzug, sowie ein Verfahren zur Herstellung der Pellets |
| WO2009004082A2 (en) | 2007-07-05 | 2009-01-08 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Anticonvulsive pharmaceutical compositions |
| ES2530047T3 (es) | 2009-02-12 | 2015-02-26 | Indiana University Research And Technology Corporation | Material y métodos para el tratamiento de trastornos del desarrollo que incluyen autismo idiopático y comórbido |
| US20100216805A1 (en) | 2009-02-25 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis using d-cycloserine combinations |
| US20110142889A1 (en) | 2009-12-16 | 2011-06-16 | Nod Pharmaceuticals, Inc. | Compositions and methods for oral drug delivery |
| US9000046B2 (en) * | 2010-09-28 | 2015-04-07 | Depomed, Inc. | Gastric retentive dosage forms for extended release of acamprosate into the upper gastrointestinal tract |
| RS53227B (sr) | 2011-03-01 | 2014-08-29 | Pharnext | Terapija neuroloških poremećaja kombinacijom baklofena i akamprosata |
| WO2012129551A1 (en) * | 2011-03-23 | 2012-09-27 | Ironshore Pharmaceuticals & Development, Inc. | Methods and compositions for treatment of attention deficit disorder |
| WO2013002584A2 (ko) | 2011-06-28 | 2013-01-03 | 주식회사 비보존 | 다중 타겟팅의 상승 효과를 유발하는 유효물질의 조합 및 그 용도 |
| AU2012345659B2 (en) * | 2011-12-02 | 2017-09-28 | Synchroneuron Inc. | Acamprosate formulations, methods of using the same, and combinations comprising the same |
| WO2014197744A1 (en) * | 2013-06-05 | 2014-12-11 | Synchroneuron, Inc. | Acamprosate formulations, methods of using the same, and combinations comprising the same |
| EP3104850A1 (en) | 2014-02-11 | 2016-12-21 | Pharnext | Combination of baclofen, acamprosate and medium chain triglycerides for the treatment of neurological disorders |
| KR102790656B1 (ko) | 2015-05-04 | 2025-04-02 | 컨플루언스 파마슈티컬스, 엘엘씨 | 아캄프로세이트의 스프링클 제형 |
-
2016
- 2016-05-04 KR KR1020177033137A patent/KR102790656B1/ko active Active
- 2016-05-04 US US15/569,937 patent/US10709668B2/en active Active
- 2016-05-04 JP JP2017558372A patent/JP7026347B2/ja active Active
- 2016-05-04 IL IL255343A patent/IL255343B2/en unknown
- 2016-05-04 HK HK18111332.4A patent/HK1252003A1/zh unknown
- 2016-05-04 WO PCT/US2016/030725 patent/WO2016179252A1/en not_active Ceased
- 2016-05-04 AU AU2016258624A patent/AU2016258624B2/en active Active
- 2016-05-04 EP EP16789996.2A patent/EP3291800A4/en active Pending
- 2016-05-04 SG SG11201708393UA patent/SG11201708393UA/en unknown
-
2017
- 2017-11-27 ZA ZA2017/08037A patent/ZA201708037B/en unknown
-
2021
- 2021-06-22 JP JP2021103349A patent/JP2021155434A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP3291800A4 (en) | 2018-09-26 |
| IL255343A0 (en) | 2017-12-31 |
| WO2016179252A1 (en) | 2016-11-10 |
| JP2021155434A (ja) | 2021-10-07 |
| IL255343B1 (en) | 2024-06-01 |
| HK1252003A1 (zh) | 2019-05-10 |
| KR20170142180A (ko) | 2017-12-27 |
| AU2016258624B2 (en) | 2021-07-29 |
| JP7026347B2 (ja) | 2022-02-28 |
| US20190046458A1 (en) | 2019-02-14 |
| SG11201708393UA (en) | 2017-11-29 |
| IL255343B2 (en) | 2024-10-01 |
| AU2016258624A1 (en) | 2017-11-02 |
| JP2018515506A (ja) | 2018-06-14 |
| US10709668B2 (en) | 2020-07-14 |
| KR102790656B1 (ko) | 2025-04-02 |
| EP3291800A1 (en) | 2018-03-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3270960A4 (en) | Vector formulations | |
| IL265856A (en) | Preparations for the administration of aflornithine | |
| IL255343A0 (en) | Essay formulations of acamprosate | |
| SG11201803029WA (en) | Novel occlusive formulations | |
| PT3474822T (pt) | Formulações de brincidofovir | |
| LT3943070T (lt) | Ilgo veikimo bedakvilino preparatai | |
| IL256400A (en) | Therapeutic uses of berberine formulations | |
| IL268678B (en) | Formulas of 1-amino-1-cyclopropane-carboxylic acid | |
| GB201522764D0 (en) | Formulations of phosphate derivatives | |
| IL272857A (en) | Cofanalisib formulations | |
| EP3277256A4 (en) | COMPOSITIONS FOR HAIR TREATMENT | |
| IL267279A (en) | Pharmaceutical formulations of suvorexant | |
| ZA201803032B (en) | Pharmaceutical compositions of dimethyl fumarate | |
| IL258420A (en) | Stable formulations of fingolimod | |
| GB201805338D0 (en) | Cosmetic formulations | |
| GB201504482D0 (en) | Novel formulations | |
| PL3490577T3 (pl) | Kompozycja do stosowania na skórę zawierająca turmerony | |
| GB2539454B (en) | Cosmetic compositions | |
| AU2015900283A0 (en) | Uses of effervescent formulations | |
| AU2016904621A0 (en) | Improved uses of new formulations | |
| GB201621277D0 (en) | Formulations | |
| GB201621867D0 (en) | Novel formulations of aprepitant | |
| GB201618110D0 (en) | Formulations | |
| GB201616366D0 (en) | Formulations | |
| GB201615754D0 (en) | Formulations |